Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Revenue (2018 - 2025)

10x Genomics (TXG) has disclosed Revenue for 8 consecutive years, with $166.0 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 0.61% to $166.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $642.8 million through Dec 2025, up 5.25% year-over-year, with the annual reading at $642.8 million for FY2025, 5.25% up from the prior year.
  • Revenue hit $166.0 million in Q4 2025 for 10x Genomics, up from $149.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $184.0 million in Q4 2023 to a low of $105.8 million in Q1 2021.
  • Historically, Revenue has averaged $144.0 million across 5 years, with a median of $147.9 million in 2023.
  • Biggest five-year swings in Revenue: surged 170.0% in 2021 and later dropped 10.3% in 2024.
  • Year by year, Revenue stood at $143.5 million in 2021, then rose by 8.85% to $156.2 million in 2022, then increased by 17.76% to $184.0 million in 2023, then decreased by 10.3% to $165.0 million in 2024, then grew by 0.61% to $166.0 million in 2025.
  • Business Quant data shows Revenue for TXG at $166.0 million in Q4 2025, $149.0 million in Q3 2025, and $172.9 million in Q2 2025.